The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The headline numbers for CarMax (KMX) give insight into how the company performed in the quarter ended November 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Although the revenue and EPS for Darden Restaurants (DRI) give a sense of how its business performed in the quarter ended November 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The headline numbers for FactSet (FDS) give insight into how the company performed in the quarter ended November 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The headline numbers for Accenture (ACN) give insight into how the company performed in the quarter ended November 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

SAN FRANCISCO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- National investor rights law firm Hagens Berman alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP). The firm is urging INSP investors who suffered substantial losses to contact its attorneys before the January 5, 2026, Lead Plaintiff Deadline.

Origin Bancorp faced a one-off earnings setback in Q3 due to a full provision on a bankrupt borrower. Despite the loss, OBK's tangible book value per share remains robust at nearly $34, trading just above 1.1x TBV. I expect earnings recovery, with EPS projected to exceed $3.60 in 2026 and tangible book value to approach $40 by 2027.

SHENZHEN, China , Dec. 18, 2025 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, innovatively launches a quantum-enhanced deep convolutional neural network image 3D reconstruction technology system. This system first utilizes quantum convolutional neural network to complete the feature extraction of input images, then generates the core parameters of the 3D model through quantum fully connected layers, and finally imports these parameters into the quantum-optimized 3D model to complete the reconstruction, forming a unique advantageous technical mode.

CEOs Accelerate Performance Improvement Initiatives, Capital Markets Activity Amid Legislative Disruption BOSTON , Dec. 18, 2025 /PRNewswire/ -- Capstone Partners, a leading middle market investment banking firm, released its 2025 Middle Market Business Owners Survey Report, with insights from privately-owned companies across the U.S. This report combines Capstone's in-depth middle market knowledge with proprietary data obtained from 401 participating owners of privately-owned, middle market companies. Conducted between August 11, 2025, and October 3, 2025, the survey captures sentiment at a pivotal moment in the U.S., identifying CEOs' decision-making processes, growth, financial, and exit plans, and value drivers that characterized middle …

Partner Reed Kathrein Investigating Alleged Assurances of "Normal" Inventory Levels Against Later Revealed Destocking Trends San Francisco, California--(Newsfile Corp. - December 18, 2025) - National shareholder rights law firm Hagens Berman is issuing a reminder to investors in James Hardie Industries plc (NYSE: JHX) as the December 23, 2025, lead plaintiff deadline approaches in a pending securities class action against James Hardie and certain of its key executives. The litigation alleges that James Hardie senior management misled investors by touting "robust" and "normal" inventory levels, while allegedly aware that channel partners were aggressively destocking as early as April 2025.

LOS ANGELES, Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inspire Medical Systems, Inc. (“Inspire” or “the Company”) (NYSE: INSP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 5, 2026.